全文获取类型
收费全文 | 1153篇 |
免费 | 42篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 58篇 |
妇产科学 | 4篇 |
基础医学 | 217篇 |
口腔科学 | 16篇 |
临床医学 | 59篇 |
内科学 | 248篇 |
皮肤病学 | 80篇 |
神经病学 | 54篇 |
特种医学 | 19篇 |
外科学 | 73篇 |
综合类 | 128篇 |
预防医学 | 30篇 |
眼科学 | 4篇 |
药学 | 107篇 |
中国医学 | 8篇 |
肿瘤学 | 100篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 7篇 |
2021年 | 11篇 |
2020年 | 12篇 |
2019年 | 84篇 |
2018年 | 93篇 |
2017年 | 35篇 |
2016年 | 24篇 |
2015年 | 19篇 |
2014年 | 80篇 |
2013年 | 61篇 |
2012年 | 54篇 |
2011年 | 90篇 |
2010年 | 61篇 |
2009年 | 56篇 |
2008年 | 71篇 |
2007年 | 60篇 |
2006年 | 54篇 |
2005年 | 44篇 |
2004年 | 36篇 |
2003年 | 25篇 |
2002年 | 23篇 |
2001年 | 13篇 |
2000年 | 140篇 |
1999年 | 11篇 |
1998年 | 10篇 |
1997年 | 5篇 |
1996年 | 6篇 |
1995年 | 6篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1984年 | 1篇 |
1981年 | 2篇 |
排序方式: 共有1206条查询结果,搜索用时 31 毫秒
41.
目的:研究急性白血病患者肾母细胞瘤基因(WT1)、黑色素瘤优先表达抗原(PRAME)、ETS相关基因(ERG)、硫氧还蛋白-2(TRX-2)基因表达及其与疾病分型、疗效的关系.方法:将本院收治的90例白血病患者纳入研究的白血病组,将同期体检健康者纳入健康组;进一步根据分型将白血病患者分为ALL组和AML组,根据化疗后疗效将白血病患者分为完全缓解组和复发组.采集患者的外周血,检测WT1、PRAME、ERG、TRX-2基因的mRNA含量.结果:白血病组血液中WT1、PRAME、ERG、TRX-2基因的mRNA含量高于对照组,差异有统计学意义(P<0.05);AML组血液中WT1、PRAME、ERG、TRX-2基因的mRNA含量高于ALL组,差异有统计学意义(P<0.05);复发组的血液中WT1、PRAME、ERG、TRX-2基因的mRNA含量高于完全缓解组,差异有统计学意义(P<0.05).结论:WT1、PRAME、ERG、TRX-2基因异常高表达与白细胞的发生有关,也与疾病的分型、化疗的效果密切相关. 相似文献
42.
43.
44.
Sang Hwa Lee Hyunkyung Kim Wook Youn Kim Hye Seung Han So Dug Lim Wan Seop Kim Sehun Kim Tae Sook Hwang 《Pathology international》2013,63(5):252-259
We evaluated p53, KRAS, BRAF and CTNNB1 mutation and p53, WT1, p16 and beta‐catenin expression in 31 ovarian high‐grade serous adenocarcinoma. Twenty‐five (80.6%) tumors contained functional mutations of p53; three frameshift, four nonsense and 19 missense mutations. None of the tumors showed KRAS, BRAF or CTNNB1 mutation. In all 18 tumors with missense mutations, ≥60% of tumor cells were strongly positive for p53 immunostaining whereas all tumors with frameshift or nonsense mutations were completely negative. Missense mutation was correlated with diffuse and strong imunoreaction and frameshift/nonsense mutation was correlated with completely negative immunoreaction (P = 0.000). Tumors with wild‐type p53 revealed a wide range of immunostaining patterns. In 27 (87.1%) and 18 (58.1%) tumors, ≥50% of tumor cells were moderate to strongly positive for WT1 and p16, respectively. A considerable intratumoral heterogeneity for p16 expression was present. None of the tumors demonstrated nuclear beta‐catenin expression. p53 mutations appear to be a powerful molecular marker for ovarian high‐grade serous adenocarcinoma. Using p53 with an appropriate interpretation criteria together with WT1, p16 and beta‐catenin, most of the high‐grade serous adenocarcinoma could be distinguished from other ovarian tumors. 相似文献
45.
Saireudee Chaturantabut Arkadi Shwartz Kimberley J. Evason Andrew G. Cox Kyle Labella Arnout G. Schepers Song Yang Mariana Acuña Yariv Houvras Liliana Mancio-Silva Shannon Romano Daniel A. Gorelick David E. Cohen Leonard I. Zon Sangeeta N. Bhatia Trista E. North Wolfram Goessling 《Gastroenterology》2019,156(6):1788-1804.e13
46.
Anja K. Büscher Bodo B. Beck Anette Melk Julia Hoefele Birgitta Kranz Daniel Bamborschke Sabrina Baig B?rbel Lange-Sperandio Theresa Jungraithmayr Lutz T. Weber Markus J. Kemper Burkhard T?nshoff Peter F. Hoyer Martin Konrad Stefanie Weber 《Clinical journal of the American Society of Nephrology》2016,11(2):245-253
Background and objectives
Treatment of congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS) is demanding, and renal prognosis is poor. Numerous causative gene mutations have been identified in SRNS that affect the renal podocyte. In the era of high–throughput sequencing techniques, patients with nongenetic SRNS frequently escape the scientific interest. We here present the long-term data of the German CNS/SRNS Follow-Up Study, focusing on the response to cyclosporin A (CsA) in patients with nongenetic versus genetic disease.Design, setting, participants, & measurements
Cross–sectional and longitudinal clinical data were collected from 231 patients with CNS/SRNS treated at eight university pediatric nephrology units with a median observation time of 113 months (interquartile range, 50–178). Genotyping was performed systematically in all patients.Results
The overall mutation detection rate was high at 57% (97% in CNS and 41% in SRNS); 85% of all mutations were identified by the analysis of three single genes only (NPHS1, NPHS2, and WT1), accounting for 92% of all mutations in patients with CNS and 79% of all mutations in patients with SRNS. Remission of the disease in nongenetic SRNS was observed in 78% of patients after a median treatment period of 2.5 months; 82% of nongenetic patients responded within 6 months of therapy, and 98% of patients with nongenetic SRNS and CsA–induced complete remission (normalbuminemia and no proteinuria) maintained a normal renal function. Genetic SRNS, on the contrary, is associated with a high rate of ESRD in 66% of patients. Only 3% of patients with genetic SRNS experienced a complete remission and 16% of patients with genetic SRNS experienced a partial remission after CsA therapy.Conclusions
The efficacy of CsA is high in nonhereditary SRNS, with an excellent prognosis of renal function in the large majority of patients. CsA should be given for a minimum period of 6 months in these patients with nongenetic SRNS. In genetic SRNS, response to CsA was low and restricted to exceptional patients. 相似文献47.
48.
49.
50.
Virtually every eukaryotic cell has an endogenous circadian clock and a biological sex. These cell-based clocks have been conceptualized as oscillators whose phase can be reset by internal signals such as hormones, and external cues such as light. The present review highlights the inter-relationship between circadian clocks and sex differences. In mammals, the suprachiasmatic nucleus (SCN) serves as a master clock synchronizing the phase of clocks throughout the body. Gonadal steroid receptors are expressed in almost every site that receives direct SCN input. Here we review sex differences in the circadian timing system in the hypothalamic–pituitary–gonadal axis (HPG), the hypothalamic–adrenal–pituitary (HPA) axis, and sleep–arousal systems. We also point to ways in which disruption of circadian rhythms within these systems differs in the sexes and is associated with dysfunction and disease. Understanding sex differentiated circadian timing systems can lead to improved treatment strategies for these conditions. 相似文献